BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Read More…
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Phone312-940-2443
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$708.90 million
Profitability
Miscellaneous
Employees2,043
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable
BioScrip (NASDAQ:BIOS) Frequently Asked Questions
What is BioScrip's stock symbol?
BioScrip trades on the NASDAQ under the ticker symbol "BIOS."
How were BioScrip's earnings last quarter?
BioScrip Inc (NASDAQ:BIOS) issued its quarterly earnings data on Tuesday, July, 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The business had revenue of $191.52 million for the quarter, compared to analyst estimates of $185.73 million. BioScrip had a negative net margin of 7.19% and a negative return on equity of 42.56%. View BioScrip's Earnings History.
When is BioScrip's next earnings date?
What price target have analysts set for BIOS?
5 equities research analysts have issued 1 year target prices for BioScrip's shares. Their forecasts range from $2.51 to $10.00. On average, they anticipate BioScrip's stock price to reach $4.95 in the next twelve months. This suggests a possible upside of 58.0% from the stock's current price. View Analyst Price Targets for BioScrip.
What is the consensus analysts' recommendation for BioScrip?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip.
What are Wall Street analysts saying about BioScrip stock?
Here are some recent quotes from research analysts about BioScrip stock:
- 1. According to Zacks Investment Research, "Option Care Health exited the third quarter with in-line loss but revenues ahead of the consensus mark. We are optimistic about the company’s huge integration-related synergy benefits. Management stated that it is expected to generate revenues exceeding $2.6 billion. The merger is expected to result in an optimized capital structure and enhance the financial strength and flexibility. The company’s consistent growth in the Infusion services business and the diverse measures adopted by management to drive growth bolsters our confidence in the stock. In the last six months, Option Care Health has consistently outperformed the industry it belongs to. On the flip side, regulatory restrictions, reimbursement cuts and a competitive landscape are a few of the factors affecting revenue growth of the legacy BioScrip over the recent past." (11/18/2019)
- 2. Barrington Research analysts commented, "We think they should have held one given that management is currently engaged in selling BIOS investors on the benefits of the pending Option Care transaction." (5/3/2019)
Has BioScrip been receiving favorable news coverage?
News coverage about BIOS stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioScrip earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for BioScrip.
Who are some of BioScrip's key competitors?
Some companies that are related to BioScrip include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).
What other stocks do shareholders of BioScrip own?
Who are BioScrip's key executives?
BioScrip's management team includes the folowing people:
- Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 54)
- Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
- Ms. Harriet Booker, Sr. VP & COO (Age 52)
- Mr. John McMahon, VP, Controller & Chief Accounting Officer (Age 54)
- Mr. Vito Ponzio Jr., Chief Admin. Officer & Sr. VP (Age 64)
Who are BioScrip's major shareholders?
BioScrip's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Gabelli Funds LLC (4.51%), GABELLI & Co INVESTMENT ADVISERS INC. (0.65%), Gamco Investors INC. ET AL (0.39%), Teton Advisors Inc. (0.12%), North Star Investment Management Corp. (0.02%) and SG Americas Securities LLC (0.02%). View Institutional Ownership Trends for BioScrip.
Which institutional investors are selling BioScrip stock?
BIOS stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Teton Advisors Inc., Gamco Investors INC. ET AL and GABELLI & Co INVESTMENT ADVISERS INC.. View Insider Buying and Selling for BioScrip.
Which institutional investors are buying BioScrip stock?
How do I buy shares of BioScrip?
Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioScrip's stock price today?
One share of BIOS stock can currently be purchased for approximately $3.14.
How big of a company is BioScrip?
BioScrip has a market capitalization of $2.21 billion and generates $708.90 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. BioScrip employs 2,043 workers across the globe.View Additional Information About BioScrip.
What is BioScrip's official website?
How can I contact BioScrip?
BioScrip's mailing address is 3000 Lakeside Dr. Suite 300N, Bannockburn IL, 60015. The company can be reached via phone at 312-940-2443 or via email at [email protected]
MarketBeat Community Rating for BioScrip (NASDAQ BIOS)
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
